Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 2,5 mg - powder for solution for injection - 2,5 mg - bortezomib mannitol boronic ester - bortezomib

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

waverley pharma europe ltd. - bortezomib mannitol boronic ester - eq. bortezomib 1 mg - powder for solution for injection - 1 mg - bortezomib mannitol boronic ester - bortezomib

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

waverley pharma europe ltd. - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib

Singapore - engleză - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - bortezomib (as a mannitol boronic ester) - injection, powder, lyophilized, for solution - bortezomib (as a mannitol boronic ester) 3.5mg/vial

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

viatris limited - bortezomib 3.5mg (as a bortezomib mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a bortezomib mannitol boronic ester) excipient: mannitol nitrogen - bortezomib mylan in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib mylan as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib mylan is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Canada - engleză - Health Canada

pfizer canada ulc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 2.5mg - bortezomib (bortezomib mannitol boronic ester) 2.5mg - antineoplastic agents

Canada - engleză - Health Canada

pfizer canada ulc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents

Canada - engleză - Health Canada

pfizer canada ulc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 1mg - bortezomib (bortezomib mannitol boronic ester) 1mg - antineoplastic agents

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - bortezomib 1mg (as mannitol boronic ester) - powder for injection - 1 mg - active: bortezomib 1mg (as mannitol boronic ester) excipient: mannitol - - in combination with melphalan and prednisone, indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. - as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. - for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - bortezomib 3.5mg (as mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as mannitol boronic ester) excipient: mannitol - - in combination with melphalan and prednisone, indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. - as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. - for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.